Clearside Biomedical (NASDAQ: CLSD)
Clearside Biomedical Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Clearside Biomedical Company Info
Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
News & Analysis
Why Clearside Biomedical Stock Surged Today
Analysts are excited about the biotech's investigational treatment for a common eye disorder.
Clearside Biomedical Stock Down 26%: The "Positive" Data That Wasn't
Sometimes press release headlines and share prices don't match up.
Why Clearside Biomedical, Inc. Stock Gained 66.1% March
Promising trial results helped trigger a short squeeze and sent the biotech's shares soaring.
Why Clearside Biomedical Is Up for a Third Straight Day
The drugmaker is raising capital at very little cost.
Why Clearside Biomedical Jumped Higher Today
After positive clinical trial data yesterday, a regulatory update on the company's other trials keeps the momentum going.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.